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Abstract
Background: Optical imaging is a promising method for the detection of tumors in animals, with speed and
minimal invasiveness. We have previously developed a lipid coated quantum dot system that doubles the
fluorescence of PEG-grafted quantum dots at half the dose. Here, we describe a tumor-targeted near infrared
imaging agent composed of cancer-specific monoclonal anti-nucleosome antibody 2C5, coupled to quantum dot
(QD)-containing polymeric micelles, prepared from a polyethylene glycol/phosphatidylethanolamine (PEG-PE)
conjugate. Its production is simple and involves no special equipment. Its imaging potential is great since the
fluorescence intensity in the tumor is twofold that of non-targeted QD-loaded PEG-PE micelles at one hour after
injection.
Methods: Para-nitrophenol-containing (5%) PEG-PE quantum dot micelles were produced by the thin layer
method. Following hydration, 2C5 antibody was attached to the PEG-PE micelles and the QD-micelles were
purified using dialysis. 4T1 breast tumors were inoculated subcutaneously in the flank of the animals. A lung
pseudometastatic B16F10 melanoma model was developed using tail vein injection. The contrast agents were
injected via the tail vein and mice were depilated, anesthetized and imaged on a Kodak Image Station. Images
were taken at one, two, and four hours and analyzed using a methodology that produces normalized signal-to-
noise data. This allowed for the comparison between different subjects and time points. For the pseudometastatic
model, lungs were removed and imaged ex vivo at one and twenty four hours.
Results: The contrast agent signal intensity at the tumor was double that of the passively targeted QD-micelles
with equally fast and sharply contrasted images. With the side views of the animals only tumor is visible, while in
the dorsal view internal organs including liver and kidney are visible. Ex vivo results demonstrated that the agent
detects melanoma nodes in a lung pseudometastatic model after a 24 hours wash-out period, while at one hour,
only a uniform signal is detected.
Conclusions: The targeted agent produces ultrabright tumor images and double the fluorescence intensity, as
rapidly and at the same low dose as the passively targeted agents. It represents a development that may
potentially serve to enhance early detection for metastases.
Background
Near infrared (NIR) imaging is a particularly promising
method of imaging since it is not invasive, requires rela-
tively simple and easy-to-use equipment, and can take
place in real time. The detection limit can be as low as
in other imaging modalities, and it is much less hazar-
dous compared to radionuclide or magnetic resonance
imaging as it does not make use of radioisotopes that
have special handling and storage requirements, both
for their use and their disposal [1]. It is also very versa-
tile and affordable. Instruments are not as expensive or
complicated as those for nuclear or magnetic imaging
[2]. In the NIR, the light penetrates much further
through the body compared to imaging in the visible
part of the spectrum [3]. This ‘absorbance window’
allows for the visualization of various phenomena deep
inside the body. Using targeted contrast agents, the
fluorescence signal can be highly localized. Examples
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receptor [4] and vascular endothelial growth factor
receptors in mice [5], or cathepsin metal-proteases in
early pancreatic cancer [3]. Detailed and precise images
of anatomical and functional aspects of animals can be
produced using actively targeted fluorophores [6,7], but
a high signal-to-noise ratio is difficult to achieve, since
NIR fluorescence is typically scattered throughout the
tissues of mice [8]. Thus, the need for highly fluorescent
targeted nanoparticles that will allow precise optical
imaging with a high signal-to-noise ratio and minimal
invasiveness and using simple instrumentation remains.
Quantum dots (QD) are semiconductor nanocrystals
made of inorganic materials, such as CdSe. They exhibit
nanosized dimensions and low polydispersity [9] Their
excitation and emission spectra depend on their size, so
that different emission spectra can be produced essentially
from the same materials simply by changing their size.
This allows simultaneous imaging of different aspects of a
pathological site [10] Their advantages for imaging include
bright fluorescence, excellent photo-stability, and variety
in possible emission spectra [11-13]. They are ideal for
optical imaging and considered reasonably safe, provided
that a stable coating is applied during their manufacture
[11,14]. Their applications include cell labeling [15], cell
trafficking studies [16], sentinel lymph node imaging [17],
lymphatic imaging [18], detection of apoptosis [19], tumor
detection, and brain imaging [20]. NIR-emitting QD that
exhibit a high molar excitation coefficient are particularly
suited for the in vivo whole body imaging. They can allow
the detection and tracking of single cells throughout the
body [21]. Since their surface properties determine their
biodistribution, various modifications of QD have been
tested to achieve long circulation times and either passive
or active targeting to areas of interest [22,23].
Lipid-core micelles are a versatile system for the
administration of drugs, DNA or imaging agents [24]
and they have proven to be a safe and highly biocompa-
tible system [25-27]. They are composed mainly of
amphiphilic block-copolymers composed of soluble
blocks, such as polyethylene glycol (PEG), and insoluble
lipid blocks, such as phosphatidylethanolamine (PE).
They self-assemble when the concentration of the
amphiphilic copolymers is above their critical micellar
concentration, exhibit both high stability and excellent
biocompatibility, and are very stable as long as their
concentration in the plasma is higher than their critical
micellar concentration. They have been used extensively
for the delivery of potent but poorly soluble drugs for
cancer therapy, like paclitaxel, or meso-tetraphenylpor-
phin in photodynamic therapy [28,29]. They have also
been used as contrast agent carriers for tumor imaging,
such as QD carriers in whole body optical imaging, as
carriers of super-paramagnetic nanoparticles for
magnetic resonance imaging and with radionuclides,
such as
111In, for gamma imaging studies [25].
Recently, we introduced a NIR contrast agent for whole
body imaging composed of QD-loaded PEG-PE micelles
(QD-Mic). The advantages of this formulation compared
to commercially available formulations include the rapid
accumulation of the agent at the tumor site (one hour
compared to four hours for the commercial formulation)
and sharply contrasted images. Using a novel quantifica-
tion method for planar imaging, we were able to deter-
mine that QD-Mic doubled the signal at the tumor site
with half the dose compared to passively targeted QD-
Mic [30]. Thus, the discrimination of tumors and internal
organs was possible. Here, we present the next step in the
development of QD-Mic, by actively targeting QD-Mic to
cancer cells. This was possible by the additional modifi-
cation of the PEG-PE coat of QD-Mic, to which a broad
variety of targeting ligands can be attached. In this study,
we used QD-Mic modification with the monoclonal anti-
body (mAb) 2C5, which has a nucleosome-restricted
specificity and recognizes a variety of cancer cells via can-
cer cell surface-bound nucleosomes released from the
apoptotically dying neighboring cancer cells [31]. mAb
2C5-targeted micelles were shown to accumulate specifi-
cally in tumors and increase the anti-tumor effect of
micelle-incorporated drugs [28]. Nucleosomes are abun-
dant on the surface of all uncontrollably proliferative
cancer cells. Recent reports from our lab demonstrate
the use of mAb 2C5-labeled micelles or liposomes, both
to established tumors and metastasis, including B16 mel-
anoma tumors [32-34]. Such immunomicelles can attach
to cancer cells even when the tumor is small, and may
serve as a vehicle for the early detection and treatment of
cancer micrometastasis [25]. Early detection (and treat-
ment) of metastasis is of great importance for the cure of
cancer, since the mortality is usually due to the develop-
ment metastatic cancers and not to the primary tumor
[35,36].
In this paper, we describe the development of 2C5-tar-
geted QD-loaded PEG-PE-based immunomicelles that
can detect small tumor sites.
Methods
Micelle characterization and stability
Micelle size was determined by the dynamic light scat-
tering (Beckman Coulter N4 Plus, USA).
Preparation of QD-Mic
Near infrared emitting CdSe QD (Qdots 800, Invitrogen,
USA) were incorporated in micelles as previously
described [25,37,38]. Briefly, a QD suspension in decane
was mixed with a four-fold volume of a 1:3 isopropanol/
methanol mixture and centrifuged at 3500 rpm for 5 min.
The supernatant was discarded and the QD pellet was
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2.7 μmoles of PEG2000-PE [N-carbonyl-methoxy-poly-
(ethyleneglycol-2000)-1,2-distearoyl-3-phospho-ethanola-
mine sodium salt] containing a 5% molar ratio of the
reactive para-nitrophenylcarbonyl(pNP)-PEG2000-PE was
mixed with 20 pmoles of QD in chloroform, and solvents
were evaporated under vacuum. The system was freeze-
dried overnight and, when necessary, hydrated in phos-
phate buffered saline (PBS), pH 7.4, or citrate buffer,
pH 5.0. Micelle size was determined.
Conjugation of 2C5 antibodies to QD-Mic
The PEG-PE/QD mixture was hydrated in 200 μlo ft h e
citrate buffer, pH 5.0, with vortexing. After an equilibra-
tion period of 1 hour, the micelles were incubated in a
3-fold excess borate buffer, pH 9.3, and mixed with a
2-fold excess of 2C5 antibody (339 μlo fa2 . 8 4m g / m l
solution). They were then dialyzed (cut-off value MW
250,000) overnight against PBS, pH 7.4 at 4°C.
Tumor inoculation in mice
Female Balb/c mice, 6-8 weeks old, (Charles River
Laboratories, Wilmington, MA) were inoculated with
tumors following a protocol approved by the
Northeastern University Institutional Animal Care and
Use Committee in accordance with the ‘Principles of
Laboratory Animal Care’ (NIH publication No. 85-23,
revised in 1996). The 4T1 murine breast cancer cells
were grown in Dulbecco Modified Eagle’sM e d i u m
(DMEM) supplemented with 10% fetal calf serum. Cells
(1.5 × 10
5 per mouse) were suspended in 150 μlo fP B S
a n di n j e c t e ds u b c u t a n e o u s l yi nt h er i g h tf l a n k .T u m o r s
developed within two weeks after the injection. The ani-
mals had free access to food and water.
Pseudometastatic melanoma model
B16F10 cells were grown in DMEM supplemented with
antibiotics and 10% fetal calf serum. Cells (8 × 10
5 per
mouse) were injected in the tail vein. In approximately
two weeks, cancer cell nodes developed in the lungs of
the animals. Control animals were sacrificed by carbon
dioxide euthanasia, lungs removed, washed in saline,
and the melanoma nodes were counted. Ex vivo white
field photographs of the lungs were taken using the
Kodak Image Station In Vivo FX (Carestestream Health,
USA). Cancer cell nodes were easily recognized as the
black spots on the lung surface.
Near Infrared mouse imaging
Contrast agents, 40 pmoles/mouse [11] were injected via
the tail vein. For the pseudometastasic model, 1/10 of
the above dose was injected. After the administration of
the contrast agents, mice were anesthetized (ketamine/
xylazine, i.p.) and depilated using a hair removal cream
(Nair, USA) prior to tumor observation. Images were
taken with a Kodak Image Station (filters: excitation
710 nm, emission 790 nm) at different angles. At the
end of the experiment, mice were sacrificed with CO2,
skin removed to avoid its scattering of the fluorescence,
and images were retaken to precisely localize the inter-
nal organs. All images were analyzed using the Kodak
Image Analysis software or the ImageJ (NIH, USA). The
regions of interest (ROI) were determined using thresh-
old analysis by comparing the whole body images with
the images after the skin was removed. The mean pixel
intensity, the background signal and the auto-
fluorescence of the animal was extracted at each time
point. The mean pixel intensity at the ROI was
expressed as an absolute number by comparison with
the scattered light (background noise from the internal
organs near the ROI), and all images were normalized
using a ROI over the hip of the mouse to compensate
for differences between the NIR images of the different
animals and time points that result from differences in
the overall image luminosity.
Detection of cancer cell nodes in the pseudometastic
model
Contrast agents were injected as previously described.
At one hour and twenty four hours after the injection of
the contrast agent, animals were sacrificed and lungs
removed. Images of the removed organs were taken as
before, both in white field and in near infrared.
Results
Micelle size
T h es i z eo ft h e2 C 5Q D - M i cw a s2 1 . 0±6 . 7n ma n d
QD-M 17.6 ± 1.2 nm. Micelles were stable at 4°C for at
least fifteen days.
Signal-to-noise ratio
Figure 1 shows the signal-to-noise for the 2C5-QD-Mic at
the area over the tumor over 4 hours. The signal-to-noise
is high within the first hour and remains practically
unchanged for the duration of the imaging. One hour after
the injection, the signal-to-noise was 47.1 ± 3.1, while at
the end of imaging it was 49.8 ± 2.7. This signal was dou-
ble that of the non-targeted QD-Mic and almost four
times higher that of the commercially available formulation
of PEG grafted quantum dots (Qtracker, Invitrogen, USA)
administered at double the dose published earlier [30].
Biodistribution of the 2C5-QD-Mic using image analysis
Figure 2 shows the distribution of the NIR signal to
the various tissues. The methodolody, as published ear-
lier, involves the generation of weighted signal-to-noise
data for the duration of the imaging experiment. The
signal-to-noise is comparable among the different time
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ence to the intrinsic fluorescence of the animal. This
analysis allowed us to express and quantify the imaging
effect of the contrast agent in vivo [39]. The highest
signal was detected in the tumor area (47.2 ± 3.1 at
one hour after the injection) and the kidney (51.4 ±
25.2). The rest of the organs exhibited a lower signal,
t h el o w e s to fw h i c hw a sf r o mt h el i v e rw i t ht h es i g n a l
intensity of 4.97 ± 0.26. This pattern remained
unchanged throughout the imaging period, so that at
four hours after the administration of the contrast
agent, the signal in the tumor area was 49.8 ± 2.7. The
liver again exhibited the lowest signal of 5.64 ± 0.82.
With the exception of the kidney and spleen, the
actively targeted 2C5 QD-Mic persisted in the tumor
area with lower affinity for other organs.
Composite images of mice injected with 2C5-QD-Mic
Figure 3 shows composite NIR images of two mice
injected with 2C5-QD-Mic one hour after the injection,
superimposed over a white field image. The signal is
v i s i b l eo n l yf r o mt h et u m o ra r e a ,i n d i c a t e db yt h e
arrow. Some signal was detected from hairs that were
not completely removed. The histograms of the pixel
values (Figure 3) verified this conclusion. Pixel values
for the tumor area had the highest values compared to
the rest of the animal body. For instance, the mean
value in the non-tumor ROI is 42.8 ± 23.5, and 62.2 ±
16.1 in the tumor area. It is of particular interest that
the pixel distribution is much narrower in the tumor
ROI. The high slope of the pixel value distribution
allowed the tumor to be identified clearly.
Composite ex vivo images of lungs from mice injected
with 2C5-QD-Mic in a melanoma pseudo-metastatic
model
In Figure 4, B16F10 melanoma cells appeared black,
while normal cells are white, since Balb/c mice are
albino. The whole body images from control mice
injected with B16F10 melanoma cells, but not the 2C5-
QD-Mic represents the intrinsic fluorescence of the
organ and showed a low level of uniform NIR fluores-
cence. The cancer cell clusters were clearly identifiable
by their black color. The background fluorescence was
uniformly distributed over the lungs. A large number of
cancer cell nodes could be seen in the white field photo-
graph. One hour after the injection of the 2C5-QD-Mic,
the NIR fluorescence was still diffuse over the entire
lungs with a pattern similar to the background fluores-
cence but with a slightly higher intensity. At 24 hours
after injection, NIR fluorescence was much less uniform.
Signal was concentrated mainly at areas near the small
clusters of cancer cells and in the periphery of the
lungs, pinpointing the smaller cancer cell clusters.
Discussion
The need for efficient contrast agents surfaced with the
development of practical and easy-to-use instruments for
NIR whole body imaging. Lipid-based coatings for QD
were proposed by us and by other labs involves encapsu-
lation of one quantum dot within a lipid envelope
[37,38,40,41]. Our approach described aimed to alter the
biodistribution profile of QD to allow for effective and
relatively rapid imaging of tumor sites. With this in
mind, we have developed a contrast agent that actively
targets tumor sites and results in a high signal-to-noise
ratio. This formulation represents a significant improve-
ment over both the commercially available pegylated
QD such as the Qtracker®, and passively targeted QD-
containing PEG-PE micelles earlier described [30], since
it allows for rapid imaging using a low dose of QD (half
that of the Qtracker®) and with a two-fold enhancement
of image intensity compared to non-targeted QD-Mic at
the same QD dose. The encapsulation of QD in a PEG-
Figure 1 Normalized signal-to-noise ratio for the fluorescence
of the tumor. Data show the ratio of the tumor fluorescence vs.
the background in the area around the tumor for 2C5 modified QD-
Mic and for QD-Mic without antibody. Error bars represent standard
deviation, N = 5.
Figure 2 Quantification of the biodistribution of 2C5 QD-M in
animals. Units represent net light intensity in the near infrared
region weighted vs. the autofluorescence of the mouse. Error bars
represent standard deviation, N = 5.
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and other ligands without using complex surface chemis-
try [40,41]. The attachment of antibodies was performed
via the micelle-incorporated reactive pNP-PEG-PE com-
ponent, which is simple and straight-forward compared
to the use of an avidin-biotin linker that exposes the
complex to opsonization by blood proteins and may
decrease its circulation time [42]. This method also offers
advantages such as simplicity and high stability over
systems composed of multiple cores in a complex lipid
system [43].
Previously, we showed that the encapsulation of QD
into the PEG-PE envelope increases the signal of QD in
the tumor area compared to unmodified “native” QD,
decreases the necessary imaging time from four hours
to one hour, and allows for a decrease of the equivalent
dose of the imaging agent by one half. The attachment
of the anti-tumor 2C5 antibody further doubles the sig-
nal by bringing more contrast agent into the tumor,
similar to earlier demonstrated enhanced imaging by
2C5-targeted contrast agents with other imaging modal-
ities [44]. This targeting allowed us to image the tumor
site with a superior signal especially to that of the liver.
This increase in the signal of 2C5 QD-M was also
reported in a variety of earlier papers from our lab
using the anti-nucleosome 2C5 anticancer antibody
which is generic to all uncontrollably proliferating cell
lines [29]. The effect of targeting has been demonstrated
in various systems, including doxorubicin liposomes
modified with the post-insertion method [33] and
micelles [45] and using different imaging modalities
such as MRI [44] or gamma imaging [46].
Antibodies are well known agents that increase the
accumulation at sites overexpressing tumor antigens
[47,48] The attachment of antibodies permits the target-
ing and visualization of surface antigens in low concen-
trations [49] and especially micrometastasis [50]. High
affinity antibodies saturate the surface of the tumor and
it becomes difficult to access the tumor mass, thus the
enhanced permeation effect can become critical [51]
and in fact, this effect, was recently modeled stochasti-
cally [52-55]. Nanoparticles accumulate mainly through
passive targeting while the tumor localization of the
nanoparticles is influenced by the antibody [56]. The
antibodies therefore are essential for the specificity of
the cell targeting while the passive accumulation is the
main force for the biodistribution of the nanoparticles
to the solid tumor [57]. This is a proof of the versatility
of our imaging methodology, that produces data as nor-
malized signal to noise, which quantify the imaging
effect (contrast) rather than simply the amount of the
nanocarrier present at the tumor site. This was also
Figure 3 Composite images (white field image superimposed with the fluorescence intensity), and cumulative histograms for the
tumor region and the whole body of two mice (A and B) injected with 2C5 QD-Mic. Fluorescence is concentrated mainly in the tumor
area, and the cumulative histograms of the frequency of pixels vs. their value for the tumor area and the body of the animal verify that the
region of interest (tumor area) has a narrow distribution of the highest value pixels from the animal body.
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a two-fold increase over the passive accumulation, using
radioactivity and calculating the ratio of the tumor vs.
the hip muscle [58].
The use of lipid-based nanoparticles for delivery of QD
has recently gained a lot of attention. A hybrid QD/catio-
nic liposome system was recently assembled [59]. This
system significantly enhanced the delivery of QD in tridi-
mensional cell culture systems, due mainly to the effect
o ft h ep o s i t i v ec h a r g eo ft h en a noparticles. Another sys-
tem used conventional immunoliposomes [60] with QD
attached via PEG spacers at the surface of the nanoparti-
cles. This latter system offers bright images due to the
presence of a large number of fluorophores per nanopar-
ticle. The simplicity of the 2C5-QD-Mic may provide an
advantage. 2C5-QD-Mic represent an improvement over
QD directly conjugated to an antibody, where the QD
antibody complex lacks the steric protection provided by
PEG coating [61].
The greater efficiency provided by the higher signal
within a shorter time should be of great benefit for cancer
imaging. Recent studies have shown that QD toxicity may
be low enough for systemic administration [62]. The small
number of studies on the use of QD for the detection of
metastases [62-64] may be attributed to the low sensitivity
of the optical imaging and the intense scattering of the
light that makes pinpointing of the source and estimation
of the size of small tumors difficult. The clear benefit of
our formulation is its high affinity towards cancer cells
introduced by the 2C5 antibody [28,65]. Although the per-
i o do f2 4h o u r sf o rt h ed e t e c t i o no fm e t a s t a s e si sl o n g e r
than that of the imaging of a larger tumor (one hour), this
is due to the need to allow the contrast agent long enough
time to circulate and attach in sufficient quantity to the
cancer cells in loci containing small numbers of such cells.
This observation also implies that both passive targeting
and antibody-mediated attachment to the tumor are
involved in the accumulation of the targeted contrast
Figure 4 Composite ex vivo images (white field image superimposed with the fluorescence intensity) of lungs from mice bearing
metastatic B16F-10 lung melanoma tumor. Left: two mice not injected with 2C5 QD-Mic. We see the clusters of melanoma cells (black) in
the lungs (white) and a low level of near infrared fluorescence. Center: two mice injected with 2C5 QD-Mic at one hour after the injection. There
is a higher level of near infrared fluorescence from the lungs. Right: two mice injected with 2C5 QD-Mic at twenty-four hours after the injection.
The fluorescence originates mainly from sites around the melanoma clusters allows detection of the metastatic sites.
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with the contrast agent and the attachment of 2C5-QD-
Mic to cancer loci follows together with the elimination of
the unbound contrast agents from the lungs as a whole.
The insufficient staining of bigger cancer masses may be
explained by an absence of 2C5-QD-Mic penetration of
the tumor cells.
The use of NIR optical imaging for the detection of
metastases has gained more attention recently and is a
useful modality for the intra-operative detection of
lymph node metastases [66]. By administering quantum
dots before the operation the lymph nodes can be visua-
lized during the operation for the removal of a breast
cancer and reduce the probability for the development of
metastases. Optical methodology has obvious advantages,
due to the simplicity of the instruments involved, for use
in the operating room [67-70]. This imaging effect is in
accordance with observations that the main thrust for
tumor accumulation is the EPR effect while the antibody
plays a helping role, which is limited to cell penetration,
especially by large lipid nanoparticles such as liposomes.
In fact, in many cases the antibodies stain only the per-
iphery of the cell cluster and are unable to penetrate dee-
p l yi n s i d et h et u m o rm a s s .T h en e te f f e c ti sar e s u l t a n t
drainage of the nanoparticles from the tumor [52,56].
However, as a modality for the detection of metastasis,
near infrared imaging has limits, because of the low sen-
sitivity of the method and the inability to detect cancer
clusters in whole body imaging. Recent developments
involving the quantification of the signal and the detec-
tion of fluorescence deep inside the body may make this
type of imaging possible and useful [71]. Although the
time necessary for imaging m a yb el o n g e rw i t hQ D - M i c
than with some radioimaging contrasts, the benefits of
using non-radiation emitting agents remain important.
As evident from our data, there is a sufficient difference
from the background signal of the healthy part of the
lungs to permit localization of cancer cells within healthy
organs. Our system may be useful to allow the detection
of a signal from remote sources throughout the body and
permit visualization of small clusters of cancer cells
before they develop into apparent tumors [72], especially
if coupled with an advanced imaging modality that cap-
tures in vivo images in real time [73,74].
Conclusion
In summary, 2C5-QD-Mic allow imaging as equally
rapid as the non-targeted micelles and produce twice
the signal at the same dose. Their production is easy
and requires no special equipment. With the develop-
ment of advanced imaging instruments that allow signal
detection deep within the body, their potential useful-
ness can be expected to be significantly enhanced.
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